pembrolizumab
merck
['keynote 189']
keynote 189 shows sustained os benefit with longer follow up and a 5y os rate of 18.4% with an os hr of 0.60. better pfs and os also observed. benefit across pdl1 strata. no new safety signals . #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him